PATENT Attorney Docket No. 224297

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Garlich et al.

Group Art Unit: 1614 Application No. 10/817,622

Examiner: Unassigned

Filed: April 2, 2004

For: TARGETED BONE MARROW

PROTECTION AGENTS

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date

In re Appln. of Garlich et al. Application No. 10/817,622

	of a first Office Action on the merits; or (d) before the mailing of a first Office A after the filing of a request for continued examination under 37 CFR 1.114.	ction
	after (a), (b), (c) or (d) above, but before the mailing date of a final action of 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action otherwise closes prosecution in the application, and includes <i>one</i> of:	
	the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97 below).	7(e)"
	the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).	
	after the mailing date of a final action under 37 CFR 1.113 or a Notice of Allow under 37 CFR 1.311, or an action that otherwise closes prosecution in the application and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$18 set forth in 37 CFR 1.17(p) (see "Fees" below).	ition, inder
	after the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or be payment of the issue fee, and within thirty days of receiving each item of information the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the feest 180 as set forth in 37 CFR 1.17(p) (see "Fees" below). NOTE: This is for original applications except applications for a design patent, filed on or May 29, 2000, wherein a paper containing only an Information Disclosure Statement in complexith 37 CFR 1.97 and 1.98 is being filed.	ation inder ee of
Copie	of the References	
\boxtimes	Copies of all of the references listed on the enclosed Form 1449 are enclosewith.	osed
	This patent application was filed after June 30, 2003. Accordingly, copies of patents and patent applications that are listed on the accompanying Form 1449 are enclosed herewith (see Official Gazette Notice of August 5, 2003). Copies of references identified on the accompanying Form 1449 are enclosed herewith.	e not
	Attached to each reference not in the English language is a concise explanation of relevance pursuant to 37 CFR 1.98(a)(3). An English-language equivalent/patern an English-language abstract, or an English-language version of the search reportation by a foreign patent office in a counterpart foreign application indicating degree of relevance found by the foreign office is being submitted in lieu of a contexplanation of the relevance pursuant to 37 CFR 1.98(a)(3).	nt, or ort or g the
\boxtimes	Copies of the PCT search report and Written Opinion are enclosed herewith.	

	Appln. of Garlich et a cation No. 10/817,62						
	parent application(furnished at that t submitted herewith The Examiner is accordance with t Procedure. In according upon for an	ed on the enclosed Forms) of the present applications. Accordingly, add, so as not to burden the respectfully requested the requirements set or rdance with 37 CFR 1.98 an earlier filing date undeviously furnished are set	ation, and collitional copies of file with du to carefully ut in the Ma (d), the detail der 35 USC 1	pies of the rest of the reference of the reference of the review the control of Pates of the parer	references were erences are not s of references. references in ent Examining at application(s)		
	U.S. APPLIC	CATIONS	St	tatus <i>(check o</i>	ne)		
U.	S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED		
1.							
2.							
3.				•			
State	Information Disclo	1.97(e) hereby states that each osure Statement was fince in a counterpart foreign.	rst cited in a	ny commun	ication from a		
	months prior to the filing of the Information Disclosure Statement. The undersigned hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.						
Stater	ment under 37 CFR	1.704(d)					
	Information Disclosoffice in a counterpany individual designation	hereby states that each sure Statement was cited part application and that gnated in 37 CFR 1.56(c) Disclosure Statement.	in a communithis commun	cation from a ication was r	a foreign patent not received by		
Fees							
	No fee is owed by the IDS Fee of \$18	he applicant(s). 30 under 37 CFR 1.17(p)	is enclosed he	erewith.			

In re Appln. of Garlich et al. Application No. 10/817,622

Date: October 13, 2004

od of Payment of Fees
Attached is a check in the amount of \$. Charge Deposit Account No. 12-1216 in the amount of \$. (A duplicate copy of this communication is enclosed for that purpose.)
rization to Charge Additional Fees
If any additional fees are owed in connection with this communication, please charge Deposit Account No. 12-1216. (A duplicate copy of this communication is enclosed for that purpose.)
ctions as to Overpayment
Credit Account No. 12-1216. Refund Xavier Pillai, Reg. No. 39,799 LEYDIG, VOIT & MAYER, LTD. Two Prudential Plaza, Suite 4900 180 North Stetson Avenue Chicago, Illinois 60601-6780 (312) 616-5600 (telephone) (312) 616-5700 (facsimile)

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT (along with any documents referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: October 13, 2004 Cotheine Studie

Please type a plu	us sign (+) inside this box	→[P E			
			E		\$		Complete if Known
Substitute for form 1449A/B/PTO			8	Хpp	lication Number	10/817,622	
INEC	DRMATION I	חופר	I OSLIDE	DEAD	Filir	g Date	April 2, 2004
	-	_			Firs	t Named Inventor	Garlich et al.
SIA	TEMENT BY	AP	PLICANI		Gro	up Art Unit	1614
_	(Use as many sheet	s as ned	essary)		Exa	miner Name	Unassigned
Sheet	1	of	1		Atto	rney Docket Number	224297

U.S. PATENT DOCUMENTS									
		U.S. Patent Do	cument						
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate			
					-				
				· · · · · · · · · · · · · · · · · · ·					
			 	<u> </u>	_				
			 		-				

				FORE	IGN PATENT DOCUMENTS			
		F	oreign Patent Docume	nt			Trans	slation
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No**
	ВМ	EP	0 512 844	A1	CELTRIX PHARMACEUTICALS, INC.	Nov. 11, 1992		
	BN	WO	02/083096	A1	ALKERMES CONTROLLED THERAPEUTICS, INC.	Oct. 24, 2002		
		l		1				

		OTHER - NON PATENT LITERATURE DOCUMENTS	-				
Examiner	Doc. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item						
Initials	No.	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*+			

Examiner Signature	Date Considered	

A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).